Skip to content
FDA Approval: Adjuvant Alectinib for Resected NSCLC episode artwork

Apr 18, 2024 38 min

FDA Approval: Adjuvant Alectinib for Resected NSCLC

from Lung Cancer Considered Hosted by IASLC

In the wake of the FDA's approval of alectinib for resected non-small cell lung cancer, Lung Cancer Considered host Dr. Narjust Florez and Dr. Benjamen Solomon discuss this development and take a deeper look at the ALINA trial, which played an important role in the drug's approval.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

FDA Approval: Adjuvant Alectinib for Resected NSCLC

0:00 38:13

No transcript yet.

Requests help us decide what to transcribe next.

Share this episode

Similar podcasts

Lung Cancer Update for Nurses Dr Neil Love Featuring one-on-one interviews conducted by Dr Neil Love with national lung cancer clinical investigators and oncology nurses, this series provides practicing clinicians including nurses and nurse practitioners with valuable information and current clinical management strategies that can be applied to optimize patient care.

Frequently asked questions

How long is this episode of Lung Cancer Considered?

This episode is 38 minutes long.

When was this Lung Cancer Considered episode published?

This episode was published on April 18, 2024.

Can I download this Lung Cancer Considered episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.